Identification of novel rapamycin derivatives as low-level impurities in active pharmaceutical ingredients

Journal of Antibiotics

Volumn 64, Issue 9, 2011, Pages 649-654

  Zech, Stephan G ^a   Carr, Michael ^a   Mohemmad, Qurish K ^a   Narasimhan, Narayana I ^a   Murray, Christopher ^a   Rozamus, Leonard W ^a   Dalgarno, David C ^a  

^a ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

chromatography; impurity isolation; mass spectrometry; natural products; NMR spectroscopy; pharmaceutical formulations

Indexed keywords

12 ETHYLRAPAMYCIN; 33 ETHYLRAPAMYCIN; RAPAMYCIN; RAPAMYCIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG IMPURITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DRUG CONTAMINATION; MAGNETIC RESONANCE SPECTROSCOPY; PHARMACEUTICAL PREPARATIONS; SIROLIMUS; TANDEM MASS SPECTROMETRY;

EID: 80053370405     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2011.61     Document Type: Article

References (40)

1. Sehgal, S., Baker, H. &Vezina, C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. 28, 727-732 (1975).
2. Kumar, Y. &Goodfellow, M. Five new members of the Streptomyces violaceusniger 16S rRNA gene clade: Streptomyces castelarensis sp. nov., comb. nov., Streptomyces himastatinicus sp. nov., Streptomyces mordarskii sp. nov., Streptomyces rapamycinicus sp. nov. and Streptomyces ruanii sp. nov. Int. J. Syst. Evol. Microbiol. 58, 1369-1378 (2008).
3. Calne, R. Y. et al. Rapamycin for immunosuppression in organ allografting. Lancet 2, 227 (1989).
4. Watson, C. J. E. et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 67, 505-509 (1999). (Pubitemid 29114208)
5. Marx, S. O. &Marks, A. R. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 104, 852-855 (2001). (Pubitemid 32778031)
6. Woods, T. C. &Marks, A. R. Drug-eluting stents. Medicine 55, 169-178 (2004). (Pubitemid 38316721)
7. Luscher, T. F. et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115, 1051-1058 (2007). (Pubitemid 46328299)
8. Neuhaus, P., Klupp, J. &Langrehr, J. M. mTOR inhibitors: an overview. Liver Transplantation 7, 473-484 (2001). (Pubitemid 32547260)
9. Sabatini, D. M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6, 729-734 (2006). (Pubitemid 44286004)
10. Faivre, S., Kroemer, G. &Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5, 671-688 (2006). (Pubitemid 44151605)
11. Harrison, D. et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392-395 (2009).
12. Blay, J. Y. Updating progress in sarcoma therapy with mTOR inhibitors. Annals Oncol. 22, 280-287 (2011).
13. Gu, J., Ruppen, M. E. &Cai, P. Lipase-catalyzed regioselective esterification of rapamycin: synthesis of temsirolimus (CCI-779). Org. Lett. 7, 3945-3948 (2005). (Pubitemid 41305680)
14. Ahuja, S. &Alsante, K. M. Handbook of Isolation and Characterization of Impurities in Pharmaceuticals (Academic Press, San Diego, CA, USA, 2003).
15. Branch, S. K. Guidelines from the international conference on harmonisation (ICH). J. Pharm. Biomed. Anal. 38, 798-805 (2005). (Pubitemid 41115785)
16. Holzgrabe, U., Wawer, I. &Diehl, B. NMR Spectroscopy in Drug Development and Analysis (Wiley Online Library, 1999).
17. Alsante, K. M. et al. Pharmaceutical impurity identification: a case study using a multidisciplinary approach. J. Pharm. Sci. 93, 2296-2309 (2004). (Pubitemid 39129627)
18. Smith, R. J. &Webb, M. L. Analysis of Drug Impurities (Wiley-Blackwell, Oxford, UK, 2007).
19. Marín, A., Espada, A., Vidal, P. &Barbas, C. Major degradation product identified in several pharmaceutical formulations against the common cold. Anal. Chem. 77, 471-477 (2005). (Pubitemid 40116825)
20. Hughes, P., Musser, J., Conklin, M. &Russo, R. The isolation, synthesis and characterization of an isomeric form of rapamycin. Tetrahedron Lett. 33, 4739-4742 (1992).
21. Hallensleben, K., Raida, M. &Habermehl, G. Identification of a new metabolite of macrolide immunosuppressant, like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry. J. Am. Soc. Mass Spec. 11, 516-525 (2000). (Pubitemid 34521239)
22. Gregory, M. A. et al. Rapamycin biosynthesis: elucidation of gene product function. Org. Biomol. Chem. 4, 3565-3568 (2006). (Pubitemid 44478817)
23. Cai, P., Tsao, R. &Ruppen, M. E. In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites. Drug Metab. Dispos. 35, 1554-1563 (2007). (Pubitemid 47296048)
24. Kessler, H., Haessner, R. &Schüler, W. Structure of rapamycin: an NMR and molecular dynamics investigation. Helv. Chim. Acta. 76, 117-130 (1993). (Pubitemid 23055388)
25. Hopson, R. E. &Peti, W. Microcoil NMR spectroscopy: a novel tool for biological high throughput NMR spectroscopy. Meth. Mol. Biol. 426, 447-458 (2008).
26. Martin, G. E. &Webb, G. A. Small-Volume and High-Sensitivity NMR Probes. Annual Reports on NMR Spectroscopy. pp 1 (Academic Press, San Diego, CA, USA, 2005).
27. Box, S. J. et al. 27-O-demethylrapamycin, an immunosuppressant compound produced by a new strain of Streptomyces hygroscopicus. J. Antibiot. 48, 1347 (1995).
28. Findlay, J. A., Liu, J. S., Burnell, D. J. &Nakashima, T. T. The structure of demethoxyrapamycin. Can. J. Chem. 60, 2046-2047 (1982). (Pubitemid 13250074)
29. Wong, G. K., Griffith, S., Kojima, I. &Demain, A. L. Antifungal activities of rapamycin and its derivatives, prolylrapamycin, 32-desmethylrapamycin, and 32-desmethoxyrapamycin. J. Antibiot. 51, 487 (1998).
30. Ritacco, F. V. et al. Production of novel rapamycin analogs by precursor-directed biosynthesis. App. Environ. Microbiol. 71, 1971-1976 (2005). (Pubitemid 40546120)
31. Schwecke, T. et al. The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin. Proc. Natl Acad. Sci. USA. 92, 7839-7843 (1995).
32. Staunton, J. &Wilkinson, B. Biosynthesis of erythromycin and rapamycin. Chem. Rev. 97, 2611-2630 (1997).
33. Park, S. R., Yoo, Y. J., Ban, Y.- H. &Yoon, Y. J. Biosynthesis of rapamycin and its regulation: past achievements and recent progress. J Antibiot. 63, 434-441 (2010).
34. Yang, W. et al. Selective epimerization of rapamycin via a retroaldol/aldol mechanism mediated by titanium tetraisopropoxide. Org. Lett. 1, 2033-2035 (1999).
35. Luengo, J. I., Konialian, A. L. &Holt, D. A. Studies on the chemistry of rapamycin: novel transformations under Lewis-acid catalysis. Tetrahedron Lett. 34, 991-994 (1993).
36. Luengo, J. I. et al. Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP interface. Chem. Biol. 2, 471-481 (1995).
37. Chung, L., Liu, L., Patel, S., Carney, J. R. &Reeves, C. D. Deletion of rapQONML from the rapamycin gene cluster of Streptomyces hygroscopicus gives production of the 16-O-desmethyl-27-desmethoxy analog. J. Antibiot. 54, 250 (2001).
38. Lowden, P. A., Bohm, G. A., Metcalfe, S., Staunton, J. &Leadlay, P. F. New rapamycin derivatives by precursor-directed biosynthesis. Chem. BioChem. 5, 535-538 (2004). (Pubitemid 39257111)
39. Goss, R. J. M. et al. An expeditious route to fluorinated rapamycin analogues by utilising mutasynthesis. Chem. BioChem. 11, 698-702 (2010).
40. Nishida, H. et al. Generation of novel rapamycin structures by microbial manipulations. J. Antibiot. 48, 657-666 (1995).